The U.S. Meals and Drug Administration has permitted Penmenvy (Meningococcal Teams A, B, C, W, and Y Vaccine) for energetic immunization in opposition to invasive meningococcal illness (IMD), in response to a press launch from GlaxoSmithKline (GSK).
Penmenvy, permitted to be used in people aged 10 by way of 25 years, targets 5 main serogroups of Neisseria meningitidis (A, B, C, W, and Y), the frequent reason for IMD. The vaccine is an injectable suspension for intramuscular use that mixes parts of GSK’s two well-established meningococcal vaccines, Bexsero and Menveo.
The vaccine’s security, tolerability, and immune response had been supported by two section 3 trials with greater than 4,800 contributors aged 10 to 25 years. The protection profile was discovered to be per GSK’s licensed meningococcal vaccines. The most typical unwanted effects reported had been ache on the injection website, fatigue, headache, muscle ache, and nausea.
“The consequences of IMD can be devastating for those who contract it, for their families and friends,” Judy Klein, president and founding father of Unity Consortium, a nonprofit group targeted on adolescent well being and immunization in the US, stated in an announcement.
“We welcome new tools to help protect more adolescents from meningococcal disease. Pentavalent MenABCWY vaccines could help address the disease by providing protection against the five vaccine-preventable serogroups in one vaccine and making it easier for adolescents to get the coverage they need.”
Approval of Penmenvy was granted to GSK.
Extra info:
Extra Info
Quotation:
FDA approves extra broadly protecting meningococcal vaccine (2025, February 18)
retrieved 19 February 2025
from https://medicalxpress.com/information/2025-02-fda-broadly-meningococcal-vaccine.html
This doc is topic to copyright. Aside from any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
